Jianmin Pharmaceutical Group (600976.SH): Ambroxol and Clenbuterol Oral Solution Approved for Market Launch

Stock News12-10

Jianmin Pharmaceutical Group Co., Ltd. (600976.SH) announced that its developed Ambroxol and Clenbuterol Oral Solution has recently been approved for market launch, as disclosed on the National Medical Products Administration website.

The oral solution is a compound preparation composed of ambroxol hydrochloride and clenbuterol hydrochloride. Ambroxol hydrochloride acts as a mucolytic agent, reducing sputum viscosity and facilitating expectoration. Clenbuterol hydrochloride, a selective β-receptor agonist, helps relax bronchial smooth muscles and promotes sputum expulsion. The two components synergize effectively to relieve cough and expel phlegm.

The product developed by the company shares identical active ingredients, excipients, dosage form, specifications, indications, administration route, and usage with the reference listed drug. With a well-established clinical application, the product is expected to address a substantial market demand.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1139691202?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-10 17:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139691202","market":"hk","top_or_hot":-1,"title":"Jianmin Pharmaceutical Group (600976.SH): Ambroxol and Clenbuterol Oral Solution Approved for Market Launch","media":"Stock News","content":"<p>Jianmin Pharmaceutical Group Co., Ltd. (600976.SH) announced that its developed Ambroxol and Clenbuterol Oral Solution has recently been approved for market launch, as disclosed on the National Medical Products Administration website.</p>\n<p>The oral solution is a compound preparation composed of ambroxol hydrochloride and clenbuterol hydrochloride. Ambroxol hydrochloride acts as a mucolytic agent, reducing sputum viscosity and facilitating expectoration. Clenbuterol hydrochloride, a selective β-receptor agonist, helps relax bronchial smooth muscles and promotes sputum expulsion. The two components synergize effectively to relieve cough and expel phlegm.</p>\n<p>The product developed by the company shares identical active ingredients, excipients, dosage form, specifications, indications, administration route, and usage with the reference listed drug. With a well-established clinical application, the product is expected to address a substantial market demand.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jianmin Pharmaceutical Group (600976.SH): Ambroxol and Clenbuterol Oral Solution Approved for Market Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJianmin Pharmaceutical Group (600976.SH): Ambroxol and Clenbuterol Oral Solution Approved for Market Launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-10 17:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jianmin Pharmaceutical Group Co., Ltd. (600976.SH) announced that its developed Ambroxol and Clenbuterol Oral Solution has recently been approved for market launch, as disclosed on the National Medical Products Administration website.</p>\n<p>The oral solution is a compound preparation composed of ambroxol hydrochloride and clenbuterol hydrochloride. Ambroxol hydrochloride acts as a mucolytic agent, reducing sputum viscosity and facilitating expectoration. Clenbuterol hydrochloride, a selective β-receptor agonist, helps relax bronchial smooth muscles and promotes sputum expulsion. The two components synergize effectively to relieve cough and expel phlegm.</p>\n<p>The product developed by the company shares identical active ingredients, excipients, dosage form, specifications, indications, administration route, and usage with the reference listed drug. With a well-established clinical application, the product is expected to address a substantial market demand.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600976","symbol_name":"健民集团","start_time":0,"source_url":"","article_id":"1139691202","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139691202","pubTimestamp":1765359183,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Jianmin Pharmaceutical Group Co., Ltd. (600976.SH) announced that its developed Ambroxol and Clenbuterol Oral Solution has recently been approved for market launch, as disclosed on the National...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600976":"健民集团","BK0250":"批发","BK0209":"零售","BK0188":"融资融券"},"translate_title":"健民药业集团（600976.SH）：氨溴索瘦肉精口服溶液获批上市","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600976":1},"content_text":"Jianmin Pharmaceutical Group Co., Ltd. (600976.SH) announced that its developed Ambroxol and Clenbuterol Oral Solution has recently been approved for market launch, as disclosed on the National Medical Products Administration website.\nThe oral solution is a compound preparation composed of ambroxol hydrochloride and clenbuterol hydrochloride. Ambroxol hydrochloride acts as a mucolytic agent, reducing sputum viscosity and facilitating expectoration. Clenbuterol hydrochloride, a selective β-receptor agonist, helps relax bronchial smooth muscles and promotes sputum expulsion. The two components synergize effectively to relieve cough and expel phlegm.\nThe product developed by the company shares identical active ingredients, excipients, dosage form, specifications, indications, administration route, and usage with the reference listed drug. With a well-established clinical application, the product is expected to address a substantial market demand.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1139691202","isCrawlerRequest":true}